Telix Pharmaceuticals Limited (TLX) Key Metrics
TLX valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $3.63B
- Enterprise value
- $4.21B
- P/E (TTM)
- 106.9
- Forward P/E
- 140.8
- PEG ratio
- —
- Price / sales
- 4.1
- Price / book
- 7.9
- EV / EBITDA
- 58.1
- Dividend yield
- —
- Beta
- 0.56
TLX key metrics, 2015–2025
Fiscal year ended December 31, 2025 · U.S. dollarsTLX returns How much profit the business earns on the capital it uses.
TLX per-share figures Results divided by the shares outstanding at year-end.
TLX financial health Debt, liquidity and how easily interest is covered.
TLX efficiency & capital use Working capital cycle and where the cash goes.
TLX valuation history
TLX returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
TLX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
TLX cash returned to shareholders
TLX price vs earnings per share
TLX key metrics
2015–2025| 2025 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|
| Valuation | |||||||||
| Market capitalization | $2.53B | — | — | — | — | — | — | — | — |
| Enterprise value | $3.02B | — | — | — | — | — | — | — | — |
| Price / sales | 2.1 | — | — | — | — | — | — | — | — |
| Price / book | 4.1 | — | — | — | — | — | — | — | — |
| EV / sales | 2.5 | — | — | — | — | — | — | — | — |
| EV / EBITDA | 37.8 | — | — | — | — | — | — | — | — |
| Earnings yield | −0.4% | — | — | — | — | — | — | — | — |
| Free cash flow yield | −3.3% | — | — | — | — | — | — | — | — |
| Share price at fiscal year-end | $7.49 | — | — | — | — | — | — | — | — |
| Per share | |||||||||
| Revenue per share | $3.57 | $0.52 | $0.03 | $0.02 | $0.01 | $0.00 | $0.25 | $0.23 | $0.39 |
| Earnings per share | −$0.03 | −$0.34 | −$0.29 | −$0.17 | −$0.12 | −$0.07 | −$0.05 | −$0.00 | −$0.00 |
| Operating cash flow per share | −$0.08 | −$0.21 | −$0.21 | $0.01 | −$0.10 | −$0.10 | −$0.05 | −$0.01 | −$0.04 |
| Free cash flow per share | −$0.25 | −$0.23 | −$0.21 | $0.01 | −$0.10 | −$0.10 | −$0.05 | −$0.03 | −$0.05 |
| Cash per share | $0.63 | $0.37 | $0.08 | $0.30 | $0.19 | $0.13 | $0.38 | $0.01 | $0.01 |
| Book value per share | $1.84 | $0.26 | $0.01 | $0.31 | $0.30 | $0.26 | $0.39 | −$0.01 | −$0.00 |
| Tangible book value per share | −$0.79 | $0.05 | −$0.20 | $0.06 | $0.10 | $0.07 | $0.37 | −$0.02 | −$0.01 |
| Dividends per share | — | — | — | — | — | — | $0.43 | — | — |
| Capex per share | $0.17 | $0.02 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.02 | $0.00 |
| Debt per share | $2.07 | $0.03 | $0.01 | $0.01 | $0.01 | $0.01 | $0.00 | $0.03 | $0.02 |
| Shares outstanding | 337.9M | 310.6M | 282.2M | 257.3M | 233.4M | 202.1M | 128.0M | 128.0M | 83.3M |
| Change in shares outstanding | +8.8% | +10.1% | +9.7% | +10.2% | +15.5% | +57.9% | 0.0% | +53.6% | — |
| Returns & profitability | |||||||||
| Return on equity (ROE) | −1.7% | −253.3% | −198.4% | −60.2% | −45.3% | −27.1% | −26.8% | — | — |
| Return on invested capital (ROIC) | 1.9% | — | — | −226.0% | −100.8% | −155.7% | −414.1% | −2.0% | −11.3% |
| Return on assets (ROA) | −0.6% | −57.0% | −60.2% | −34.5% | −31.1% | −21.6% | −18.3% | −0.2% | −0.7% |
| Return on tangible assets | −1.2% | −54.5% | −161.1% | −47.5% | −49.4% | −37.1% | −12.9% | −0.3% | −0.8% |
| Free cash flow margin | −6.9% | −44.4% | −798.7% | 32.8% | −681.1% | — | −19.0% | −13.3% | −11.6% |
| Financial health | |||||||||
| Total debt | $699.8M | $10.4M | $2.5M | $2.2M | $2.1M | $1.7M | $345,433 | $4.2M | $1.8M |
| Cash & short-term investments | $212.5M | $116.3M | $22.0M | $77.9M | $44.6M | $25.8M | $48.8M | $840,886 | $750,142 |
| Net debt | $487.2M | −$105.9M | −$19.5M | −$75.7M | −$42.5M | −$24.0M | −$48.4M | $3.4M | $1.0M |
| Debt / equity | 1.12 | 0.13 | 1.18 | 0.03 | 0.03 | 0.03 | 0.01 | — | — |
| Debt / assets | 0.40 | 0.04 | 0.02 | 0.01 | 0.02 | 0.02 | 0.01 | 0.23 | 0.10 |
| Net debt / EBITDA | 6.10 | — | — | — | — | — | — | — | — |
| Current ratio | 1.43 | 2.02 | 1.25 | 4.69 | 5.52 | 4.35 | 33.74 | 0.61 | 0.71 |
| Quick ratio | 1.27 | 1.96 | 1.16 | 4.66 | 5.47 | 4.27 | 33.54 | 0.43 | 0.48 |
| Interest coverage | 0.5 | -226.4 | -415.2 | -37.6 | -15.0 | — | -693.5 | -0.1 | -0.3 |
| Working capital | $147.8M | $87.7M | $9.6M | $73.7M | $48.1M | $27.6M | $48.1M | −$5.5M | −$3.4M |
| Invested capital | $1.11B | −$25.9M | −$17.3M | $3.3M | $27.6M | $28.9M | $879,270 | $1.6M | $809,112 |
| Tangible asset value | −$265.8M | $15.5M | −$56.2M | $15.6M | $23.9M | $13.5M | $47.8M | −$2.8M | −$1.2M |
| Net current asset value | −$653.8M | −$2.1M | −$58.6M | $14.8M | $26.2M | $12.1M | $47.7M | −$11.7M | −$9.9M |
| Graham net-net per share | −$2.23 | −$0.11 | −$0.24 | $0.04 | $0.09 | $0.04 | $0.37 | −$0.12 | −$0.16 |
| Capital allocation | |||||||||
| Dividends paid | — | — | — | — | — | — | $54.8M | — | — |
| Share buybacks (net) | — | $7.8M | — | $130,000 | $759,601 | $1.0M | $3.0M | $840,886 | $750,142 |
| Dividends + buybacks / free cash flow | — | — | — | 7.6% | — | — | — | — | — |
| Capex / revenue | 4.7% | 4.4% | 17.6% | 4.8% | 11.6% | 101.8% | 0.0% | 9.6% | 0.7% |
| Capex / operating cash flow | — | — | — | 12.7% | — | — | — | — | — |
| Capex / depreciation | 1.74 | 1.31 | 0.26 | 0.05 | 0.10 | 28.39 | 1.49 | 1.17 | 0.07 |
| Stock-based compensation / revenue | — | 5.1% | 17.4% | 45.0% | 36.4% | 364.9% | 0.3% | — | — |
| R&D / revenue | 21.3% | 36.1% | 449.4% | 442.8% | 607.2% | 9,578.7% | 9.4% | 0.0% | 0.2% |
| SG&A / revenue | 29.6% | 54.4% | 541.0% | 345.4% | 323.5% | 4,651.9% | 8.4% | 0.1% | 0.2% |
| Efficiency | |||||||||
| Days sales outstanding | 62.8 | 59.3 | 841.8 | 952.2 | 1,151.0 | 8,846.5 | 27.7 | 51.4 | 44.7 |
| Days of inventory on hand | 35.9 | 25.8 | 19.3 | 105.9 | 14.1 | 10.7 | 140,685.5 | 44.4 | 37.8 |
| Days payables outstanding | 69.3 | 80.3 | 83.5 | 1,151.6 | 121.3 | 40.0 | 112,951.3 | 31.9 | 24.3 |
| Cash conversion cycle (days) | 29.3 | 4.7 | 777.6 | -93.4 | 1,043.7 | 8,817.2 | 27,761.9 | 64.0 | 58.2 |
| Receivables turnover | 5.82 | 6.16 | 0.43 | 0.38 | 0.32 | 0.04 | 13.19 | 7.10 | 8.16 |
| Payables turnover | 5.26 | 4.54 | 4.37 | 0.32 | 3.01 | 9.12 | 0.00 | 11.45 | 15.00 |
| Inventory turnover | 10.17 | 14.14 | 18.93 | 3.45 | 25.93 | 34.22 | 0.00 | 8.21 | 9.66 |
| Asset turnover | 0.68 | 0.88 | 0.06 | 0.04 | 0.04 | 0.00 | 0.91 | 1.61 | 1.81 |
| Average receivables | $207.3M | $26.0M | $17.5M | $13.6M | $11.0M | $4.7M | $2.4M | $4.1M | $4.0M |
| Average payables | $107.4M | $14.3M | $8.8M | $6.4M | $5.1M | $1.8M | $1.2M | $1.9M | $1.7M |
| Average inventory | $55.5M | $4.6M | $2.0M | $587,500 | $592,262 | $469,872 | $1.5M | $2.6M | $2.6M |
| Intangibles / total assets | 50.1% | 25.3% | 54.5% | 40.2% | 45.0% | 51.4% | 3.0% | 5.5% | 5.7% |
Computed from TLX's annual financial statements (latest annual report filed February 20, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
TLX valuation and financial ratios
Based on the latest twelve months, the trailing P/E is 106.9 and the forward P/E is 140.8. Telix Pharmaceuticals earned a return on equity of −1.7% and a return on invested capital of 1.9% in fiscal 2025. It ended the year with $699.8 million of debt and $212.5 million in cash and short-term investments, net debt of $487.2 million. The share count rose 305.5% from 83.3M to 337.9M over 8 years.
See the TLX income statement, the TLX chart for price history, or the TLX stock overview for the latest quote and news.
TLX key metrics FAQ
What is Telix Pharmaceuticals's P/E ratio?
Telix Pharmaceuticals's trailing P/E ratio is 106.9 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 140.8. At the end of fiscal 2025 it was —.
What is Telix Pharmaceuticals's EV/EBITDA?
Telix Pharmaceuticals's enterprise value was 37.8 times EBITDA at the end of fiscal 2025 (enterprise value $3.0 billion, EBITDA $79.8 million); the current EV/EBITDA is 58.1.
What is Telix Pharmaceuticals's return on equity?
Telix Pharmaceuticals's return on equity (ROE) was −1.7% in fiscal 2025: net income of -$10.7 million on average shareholders' equity of $351.1 million.
What is Telix Pharmaceuticals's ROIC?
Telix Pharmaceuticals's return on invested capital was 1.9% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Telix Pharmaceuticals have?
Telix Pharmaceuticals had total debt of $699.8 million at the end of fiscal 2025, a debt-to-equity ratio of 1.12 and $487.2 million of net debt (6.10 times EBITDA).
What is Telix Pharmaceuticals's free cash flow yield?
Telix Pharmaceuticals generated -$82.8 million of free cash flow in fiscal 2025, a free cash flow yield of −3.3% on its market value at year-end ($2.5 billion).
What is Telix Pharmaceuticals's current ratio?
Telix Pharmaceuticals's current ratio was 1.43 at the end of fiscal 2025: current assets were 1.43 times current liabilities.